ArticleAIDS (London, England)2026
A novel measure of antiretroviral activity in cerebrospinal fluid and association with HIV persistence and cognitive function.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveHIV has been shown to persist in cerebrospinal fluid (CSF) in persons on antiretroviral therapy (ART), which may be linked with inadequate ART exposure, potentially contributing to neurocognitive dysfunction. Our objective was to compare ART regimen inhibitory activity in CSF with participant outcomes.
methodsA5321 is a prospective study of HIV reservoirs among persons with HIV on long-term ART with documented suppressed viremia; 44 participants who underwent lumbar puncture were evaluated. CSF trough concentrations were determined and inhibitory quotients (IQs) calculated for each antiretroviral (ARV) in a participant's regimen as the ratio of CSF concentration to literature values for in vitro HIV IC 50or90 . The geometric mean (GM) of CSF IQs of all drugs in each participant's ART regimen was calculated (CSF ART-IQ GM ). Statistical analyses evaluated associations among ART-IQ GM and CSF HIV DNA, biomarkers and global deficit score (GDS).
resultsThe median (Q1, Q3) CSF ART-IQ GM was higher in those with undetectable vs. detectable CSF cell-associated HIV DNA (CA-DNA): 0.9 (0.5, 1.6) vs. 0.5 (0.3, 0.9), P = 0.027. Higher ART-IQ GM was associated with lower GDS (i.e., better global cognitive function, Spearman: -0.30, P = 0.05). There was no association between CSF inflammatory biomarkers and ART-IQ GM .
conclusionsThe CSF ART-IQ GM is a novel approach to assess ART regimen activity. This metric was associated with lack of CSF CA-DNA detection and better GDS, which suggests ART regimen activity affects HIV persistence in CSF. This tool motivates further investigations of relationships between regimen activity and biomarkers of HIV persistence in CSF and in other anatomic HIV reservoirs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.